U.S. Tobacco Stock News

IonQ acquired SkyWater Technology, a U.S. based quantum foundry, creating what it describes as a vertically integrated, full stack trapped ion quantum platform with domestic manufacturing. The company deployed the Romanian National Quantum Communication Infrastructure, one of the largest quantum secure networks in Europe. These moves expand IonQ's role across quantum computing, networking, and security, and may influence how investors assess its competitive position. IonQ (NYSE:IONQ) is...

Okta recently reported past-quarter results showing revenue and adjusted earnings growth, driven largely by enterprise uptake of its newer AI-focused security tools and identity offerings. The launch of Auth0 for AI Agents and an expanded AI security partnership with the PGA of America highlight Okta’s push into securing emerging AI-driven workloads and user experiences. With Okta leaning further into AI identity security via Auth0 for AI Agents, we’ll now examine how this reshapes its...

Wondering whether Stoke Therapeutics at around US$33.78 is starting to look expensive or if there is still value on the table? This article walks through the key numbers so you can judge for yourself. The stock has been volatile, with a 4.8% decline over the last 7 days, an 11.3% gain over 30 days, a 9.3% return year to date, a 345.6% return over 1 year, a 266.0% return over 3 years, and a 34.9% decline over 5 years. These price swings sit against a backdrop of ongoing attention on Stoke...

If you are looking at AGNC Investment and wondering whether the current share price gives you enough value for the risk you are taking, this article is built to walk you through that question step by step. The stock last closed at US$11.00, with returns of 2.7% decline over 7 days, 3.5% decline over 30 days, a 0.6% gain year to date, 24.4% over 1 year, 62.2% over 3 years, and 31.3% over 5 years. Recent price moves have been accompanied by ongoing attention on AGNC Investment's interest rate...

Fidelis Insurance Holdings Limited recently reported past fourth quarter 2025 results showing revenue of US$600.9 million and net income of US$117.8 million, alongside a full-year profit of US$225.5 million, while also maintaining its quarterly dividend at US$0.15 per share. At the same time, Fidelis completed and expanded sizeable share repurchase programs, including an agreement to buy all remaining shares held by founding shareholder CVC Falcon Holdings at US$19.00 per share, a price...

Novo Nordisk (NYSE:NVO) received FDA approval for three new pediatric indications for its long acting growth hormone, Sogroya. The approvals cover multiple growth disorders in children in the US, expanding Sogroya’s treatment reach. The company also entered a partnership with Vivtex to work on oral biologic treatments for obesity, diabetes, and related conditions. These updates come as Novo Nordisk shares trade at $36.66, with the stock showing a 10.2% return over the past five years but a...

Formula One Group (FWON.K) is back on investors’ radar after year-end results showed higher revenue and a return to profit, alongside a fresh five-year Concorde Agreement and expanded global media partnerships. See our latest analysis for Formula One Group. At a share price of US$88.81, Formula One Group has given investors a 1-year total shareholder return decline of 2.5%, although the 3-year and 5-year total shareholder returns of 28.2% and 100.5% suggest longer term holders have seen...

CACI International (NYSE:CACI) has announced and priced a $500 million senior notes offering. The company plans to use the proceeds to help fund its acquisition of ARKA Group L.P. The transaction affects CACI International's capital structure and future debt obligations. For investors watching NYSE:CACI, this new senior notes offering comes at a time when the stock is trading at $629.75. The shares show longer term returns of 78.4% over the past year, 110.5% over three years, and 182.1%...

If you are wondering whether Palantir Technologies' current share price still makes sense after everything that has happened with the stock, this article will walk you through what the current market price could be implying about its value. The stock closed at US$147.22, with returns of 9.7% over the last 7 days, a 0.4% decline over 30 days, a 12.3% decline year to date, 63.3% over 1 year, and a very large gain over 3 years, which naturally raises questions about how much optimism is already...

U.S. Space Force has reopened competition for the SCAR program, a contract previously awarded to AeroVironment subsidiary BlueHalo. The SCAR award has been a meaningful part of AeroVironment’s contracted backlog, so the rebid introduces uncertainty around future revenue. At the same time, AeroVironment is investing in expanded U.S. manufacturing in Albuquerque, New Mexico, to support directed energy and space technology production. AeroVironment (NasdaqGS:AVAV), which last closed at $228.3,...

Conference appearance puts U.S. Gold in focus U.S. Gold (USAU) is set to present at the Emerging Growth Virtual Conference on February 25, 2026. Executive Chairman Luke Anthony Norman is expected to speak, drawing attention to potential commentary on projects and capital needs. See our latest analysis for U.S. Gold. At a share price of US$18.84, U.S. Gold has seen a 7 day share price return of 4.96% and a 30 day share price return of 8.65%. The 1 year total shareholder return of 125.90% and 3...

Agios Pharmaceuticals recently announced that the Emirates Drug Establishment in the UAE approved PYRUKYND (mitapivat) as the first and only medicine for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. This approval, supported by global Phase 3 ENERGIZE and ENERGIZE-T data and backed by a regional partnership with NewBridge Pharmaceuticals, strengthens Agios’s push into Gulf markets for rare blood disorder treatments. Next, we’ll examine...

If you are wondering whether Ross Stores is still good value after its run in the market, it helps to separate the share price story from what the underlying business may be worth. The stock last closed at US$197.64, with a 1.5% decline over 7 days, a 4.8% gain over 30 days, and returns of 8.2% year to date, 47.0% over 1 year, 85.9% over 3 years, and 67.2% over 5 years. This naturally raises questions about what is already priced in. Recent coverage around Ross Stores has largely focused on...

Axos Financial (AX) has been in focus after higher than expected inflation data raised doubts about near term rate cuts, putting pressure on bank stocks and sharpening investor attention on interest rate risk. See our latest analysis for Axos Financial. Despite the inflation driven sell off that recently hit Axos Financial, the current US$89.97 share price sits above its 90 day level, and the 1 year and 3 year total shareholder returns of 39.92% and 97.82% suggest momentum has been positive...

Why Twilio’s latest earnings and KPN partnership are drawing fresh attention Twilio (TWLO) is back on investors’ radar after fourth quarter results came in ahead of guidance, organic revenue growth impressed analysts, and fresh Buy ratings followed, helped by expanding AI focused products and the new RCS partnership with KPN Netherlands. See our latest analysis for Twilio. At a share price of $123.51, Twilio has seen an 8.48% 7 day share price return but a 10.73% decline year to date. The 1...

Aflac stock after recent performance Aflac (AFL) has been relatively steady in recent trading, with a 1-day return of about a 0.8% decline and a flat move over the past week, keeping investors focused on its longer-term record. See our latest analysis for Aflac. At a share price of US$112.43, Aflac’s recent pullback sits against a firmer backdrop, with a 30 day share price return of 1.33% and a 5 year total shareholder return of 151.14%. This suggests sentiment has been supportive over time...

Harry Potter tie-in puts McCormick’s Butterbeer flavors in focus McCormick (MKC) is back in the spotlight after partnering with Warner Bros. Discovery to launch limited edition Harry Potter Butterbeer Finishing Sugar and Butterbeer Flavor across major retailers. The collaboration gives investors a fresh data point on how licensing deals and themed products might influence McCormick’s broad consumer portfolio, which already spans spices, sauces, seasonings, and dessert products worldwide. See...

AbbVie recently reported positive topline Phase 3 results from its AFFIRM trial, showing risankizumab (SKYRIZI) subcutaneous induction led to significantly higher clinical remission and endoscopic response rates than placebo in adults with moderately to severely active Crohn’s disease, with safety consistent with prior data. Because AFFIRM included patients who had already failed multiple advanced therapies, the results highlight SKYRIZI’s potential to address a difficult-to-treat Crohn’s...

The Morning Bull - US Market Morning Update Wednesday, Mar, 4 2026 US stock futures are slightly softer this morning, with E-mini S&P 500 contracts down about 0.2%, as investors juggle stubborn inflation worries and mixed global growth signals. The US 10 year Treasury yield is holding near 4.06%, which indicates borrowing costs remain relatively high and keeps pressure on areas like real estate and smaller, debt heavy companies. At the same time, a large 5.6 million barrel build in US oil...

What Medline’s recent fundamentals mean for investors Medline (MDLN) has drawn fresh attention after investors focused on its latest reported fundamentals, including US$28.4b in revenue, US$1.2b in net income, and single digit annual growth rates across both measures. See our latest analysis for Medline. Despite US$28.4b of revenue and US$1.2b of net income drawing focus to fundamentals, Medline’s recent 1-day share price return of a 3.18% decline and 7-day share price return of an 11.2%...

Onto Innovation Inc. recently reported fourth-quarter 2025 sales of US$266.87 million and full-year 2025 sales of US$1.01 billion, alongside weaker profitability, and issued first-quarter 2026 guidance calling for US$275 million to US$285 million in revenue with a GAAP diluted EPS range of US$0.74 to US$0.84. Despite pressure on net income, the company’s stronger-than-expected international revenue, especially in Japan, Taiwan, and Southeast Asia, has reinforced investor interest in its...

In February 2026, Peoples Group announced a major partnership with Fiserv to power its next-generation Canadian payments infrastructure using Fiserv’s Enterprise Payments Platform and DNA core in the public cloud, supporting instant payments, always-on connectivity, and ISO 20022 data ahead of Payments Canada’s Real-Time Rail rollout. This represents one of Peoples Group’s largest technology investments and highlights how Fiserv’s cloud-based payments stack is increasingly becoming a...

If you are wondering whether Intuitive Surgical's current share price still reflects good value, you are not alone; many investors are asking the same question before making their next move. The stock last closed at US$497.42, with returns of 0.7% over 7 days, a 1.3% decline over 30 days, an 11.5% decline year to date and a 10.9% decline over 1 year, set against gains of 115.6% over 3 years and 112.3% over 5 years. Recent attention on Intuitive Surgical has centred on its position in robotic...

Key recent performance for Semtech (SMTC) With no single headline event in focus, Semtech (SMTC) has still been active on investors’ radar, supported by recent share price moves and the latest reported financial results. The stock shows a 6.4% decline over the past day, while the past month return is about 13% and the past 3 months return is about 23%. Over the past year, the total return is about 150% and the 3 year total return is described as very large. On the fundamentals side, Semtech...